Issue Date: November 28, 2016 | Web Date: November 23, 2016
Lilly Alzheimer’s drug fails
In yet another blow to the amyloid hypothesis, Eli Lilly & Co. said today that its Alzheimer’s treatment solanezumab failed in a Phase III study. Shares of Lilly were down as much as 15% on the news.
For more than a decade, Alzheimer’s drug developers have focused their efforts on trying to prevent or remove the amyloid plaques coating the brains of people with the disease. Solanezumab, which binds to soluble, monomeric forms of amyloid-β, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society